Public Company Resource Hub

Join Cooley’s public companies group for our SEC Annual Reporting Workshop. More practical than ever before, this series features a number of interactive sessions focused on drafting various SEC disclosures, identifying pitfalls you need to avoid and offering the type of practical guidance that companies need to tackle another complicated proxy season.

Join Cooley lawyers Beth Sasfai, Emma Bichet and Michael Mencher as they discuss the major environmental, social and governance (ESG) topics that companies should be looking at in a rapidly evolving regulatory environment.

Join members of Cooley’s public companies and cyber/data/privacy groups as we analyze 8-K filing trends for cybersecurity incidents in the past year, offer strategies and considerations for companies when filing 8-Ks, and review our annual 8-K report covering these topics.

Current Securities and Exchange Commission guidance forces companies into a catch-22, where a decision to provide personal security protection will require disclosure and draw additional scrutiny, and potentially the ire of proxy advisory firms, while a decision to limit or not provide such protection to avoid disclosure or reduce the amount disclosed will potentially put executives’ safety at risk.

The Securities and Exchange Commission (SEC) adopted final rules and form amendments intended to improve access to and management of accounts on its Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system that are related to certain technical changes to EDGAR (collectively referred to as EDGAR Next). EDGAR Next will impact, most notably, public company and investment fund administrators, individuals (Section 16 officers and directors) and filing agents. Early coordination among these parties – well in advance of the September 15, 2025, compliance deadline – will be critical to ensure a smooth transition to EDGAR Next.

Learn more about the Securities and Exchange Commission’s Office of the Whistleblower annual report, UPS’ $45 million penalty for improperly valuing a business unit, SEC charges against Kiromic BioPharma and two former C-suite executives for misleading investors about the status of Food and Drug Administration reviews, SEC charges against a former CEO for insider trading in advance of a negative earnings announcement, the Fifth Circuit vacating Nasdaq’s board diversity listing standards, the SEC’s approval of further amendments to Nasdaq’s reverse stock split requirements, and California giving companies an extra year before fully enforcing new climate reporting rules.